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Summary. Mortality figures were calculated for a group of
717 Dutch haemophiliacs over the period 1973-86. Follow-
up was on average 10-9 years; no patients were lost to follow-
up. The data were compared to the general male population
by actuarial methods and patient-year analysis. Forty-three
patients died, while 20 deaths were expected in a hypotheti-
cal group of non-haemophiliacs of the same age distribution.
Hence, overall mortality was 2·l times higher than in the
general population. This leads to a calculated life expectancy
of 66 years, äs compared to 74 years in the general male
population. Mortality did not differ much by severity of
haemophilia. A possibly beneflcial effect of prophylaxis on
longevity was observed. Haemorrhage occurred in half of all
deaths and among these traumatic bleeding was the most
prevalent. The number of deaths due to ischaemic heart
disease was significantly lower (80% reduction) than
expected and therefore the authors conclude that haemophi-
lia offers protection against ischaemic heart disease. Cancer
mortality was significantly higher (2-5 times) than expected.
Life expectancy in haemophilia was very low until the
introduction of coagulation factor preparations made effec-
tive replacement therapy possible. Patients with severe
haemophilia usually did not live beyond early adulthood,
while even the life expectancy in mild haemophilia was
reduced to about two-thirds of the normal life span (Sjölin,
1960; Ramgren, 1962; Ikkala et al, 1982; Larsson, 1985).
Recently, Larsson (1985) reported a much improved median
life expectancy of 57 years in severe haemophilia over the
period 1961-80. Although this flgure was still markedly
below that of the general population, he also observed that
the death rates for the younger patients in the last 10 years of
his study were approaching those of the general Swedish
population. Johnson et al (1985) found the age-adjusted
mortality among United States haemophiliacs during 1978-
82 to be 2-3 times äs high äs that of the general male
population. Some deaths may have been missed, however,
since this result was based on reported deaths and visits to
haemophilia centres, rather than on a cohort study.
Before 1960, virtually all deaths in haemophilia were
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caused by haemorrhage (Nour-Eldin, 1961; Ramgren, 1962;
Ikkala et al, 1982; Wolff et al, 1986). The increased life
expectancy and the concomitant increased average age of
haemophiliacs now make it possible to study the occurrence
of other causes of death in haemophilia and to compare these
with the expected frequencies based on mortality figures from
the general population. We set out to calculate mortality
figures in haemophilia, based on haemophilia surveys that
we started in 1973.
METHODS
The data were derived from haemophilia surveys carried out
in 1973, 1978 and 1986. These surveys consisted of mail
questionnaires sent to the Dutch haemophiliacs. The patients
were enrolled through the major Dutch haemophilia treat-
ment centres and the Dutch Haemophilia Society.
Severity of haemophilia was deflned by the percentage of
factor VIII or factor IX clotting activity: severe haemophilia
less than 1%, moderate haemophilia 1-5%, and mild haemo-
philia more than 5% clotting activity. If necessary, the
Information from the patients' forms was supplemented with
data from the haemophilia treatment centres.
Follow-up was performed for the respondents of the first
two surveys and extended from either l January 1973 or l
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Table I Distribution of patients by type and seventy of
haeraophüia
Type A Type B
Seventy n o//o
Inhibitor Mean age at
patients (n) entrance (yr)
Severe
Moderate
Mild
275
139
202
45
23
33
46
30
25
46
30
25
24
4
2
20
21
28
2
2
2
All 616 101 30 23 0
June 1978 up to l January 1986, which were the closmg
dates of the three surveys Information was obtamed about all
717 patients who responded to the previous surveys, either
frora their response to the latest survey, or by inquines of the
mumcipal registnes In this way none of the mdividuals was
lost to follow-up
We compared mortality m our patient group with the
general population m two ways Both allowed the expression
of mortality äs a ratio of observed over expected mortality
First, the actuanal survival was calculated by life table
methods, and compared with the survival of a hypothetical
cohort of identical age distnbution from the general male
population So, we mcorporated the national mortality
flgures for all consecutive years of the follow-up penod
(Netherlands Central Bureau of Statistics, 1973-86, 1984)
Secondly, we compared cause-speciflc mortality by the
patient-year method This calculation was performed by
multiplymg the number of patient-years of follow-up for each
age category of the cohort with the correspondmg cause-
specific mortality rates in the general male population, and
summmg over the age classes The observed/expected ratio
arnved at m this way is the standardized mortality ratio
(SMR) In the calculation of cause specific mortality the
population flgures of 1979 were used For statistical analysis
we used the Poisson distnbution to calculate confidence
hmits and exact significance levels and chi-square tests
RESULTS
Mortality flgures were calculated for a cohort of 717 patients,
consisting of the respondents of the 1973 and 1978 surveys
A response rate of 84% to the flrst and 70% to the second
survey resulted in 481 patients entering the study m 1973,
whüe an additional 236 entered in 1978 An extensive and
by all practical means exhaustive search led to a mailing to
1162 haemophihacs in our latest survey m 1986 This
number, considermg a population of 14 5 million Dutch,
gives a prevalence of eight per 100 000, so it can be inferred
that the cohort of 717 patients formed about 65% of all Dutch
haemophihacs, when we take the growth of the general
population into account Nme hundred and thirty-flve
patients responded in our 1986 survey (80%) Mean follow-
up was 10 9 years None of the 717 patients was lost to
follow-up The mean age at entrance m the study was 23
years Table I shows the general charactenstics of the cohort
of 717 patients
965
o 926
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Fig l Cumulative survival in haemophika 1973 86 The open line
shows the observed survival over the mterval 1973-86 The closed
line shows the expected survival The distance from 100% is the
mortality 7 4% observed and 3 5 % expected
Forty-three patients died dunng the study mterval, while
20 4 deaths were expected when we applied age-speciflc
population mortality rates Therefore, relative mortality, the
ratio of observed over expected mortality, was 2 l, i e
mortality was twice äs high in the haemophihacs äs in the
general male population (Fig 1) Relative mortality was 2 9
in severe, and only l 6 m mild haemophilia When we
excluded the small group of Inhibitor patients, however,
relative mortality did not differ much by seventy of haemo-
philia The mean age of death was 49 years The median life
expectancy was calculated also by life table method, by
applymg the population mortality flgures multiphed by the
relative mortality at each age mterval For this calculation to
be vahd an equal distnbution of relative mortality over age
has to be assumed The median life expectancy is the age at
which half of a hypothetical cohort of newborns had died It
was 74 years for the Dutch male population, and estimated at
66 years for a relative mortality of 2 l (Table II)
Among the patients with severe haemophilia 24 (7%) had
an mhibitor Six of these patients died, but only 14 of the 297
patients without an mhibitor died (χ2 = 12 4, P<0 0004) |
Inhibitor patients had a 5 3 times higher nsk of dymg than
the patients without an mhibitor (95% confidence mterval
l 9-11 5) This was not due to a difference m age on the
contrary, the mhibitor patients were on average shghtly
younger (half a year) at their entrance to the study than the
other patients with severe haemophilia
One hundred and twenty-nme (43%) of the 297 patients
with severe haemophilia, mhibitor patients excluded,
received prophylactic Substitution therapy durmg the whole
or, more frequently, part of the study mterval Only three
deaths occurred in the prophylaxis group, while 11 patients
died among the 168 haemophihacs who did not receive
prophylaxis Part of this difference was caused by a different
age-distnbution patients receivmg prophylaxis were on
average 5 years younger at their entrance in this study After
age adjustment, however, mortality was still lower m the
patients who received prophylactic treatment the relative
mortality was l 9, äs compared to 2 5 among the patients
who were not treated prophylactically This difference was
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Table II. Relative mortahty m haemophilia by seventy of haemophilia*
73
Group
Includmg
AH
Severe
Moderate
Mild
Excludmg
All
Severe
Moderate
Mild
Patient- Relative 95%
No of years No mortahty, conftdence
patients (yr) ofdeaths O/E interval
patients
717
321
169
227
patients
687
297
165
225
with an
7788
3653
1863
2263
with an
7467
3404
1817
2247
Inhibitor
43
20
10
13
mhibitor
36
14
10
12
2
2
2
1
1
2
2
1
1
9
3
6
8
3
3
5
1
1
1
0
1
1
1
0
51-2
77-4
09-4
86-2
28-2
27-3
11-4
76-2
80
48
18
77
51
90
26
58
Mediän
hfe-
expectancy
(yr)
66
63
65
69
68
65
65
70
* Relative mortahty is the ratio of observed over expected mortahty, äs found
by life table method The 95% confidence interval apphes to this ratio Mediän
hfe expectancy was also calculated by life table method, with apphcation of the
appropnate relative mortahty over each 1-year interval Normal median hfe
expectancy (males, 1976-80) is 74 years
Table IV. Observed and expected frequency of death causes*
Table III. Causes of death1
Cause
Bleedmg
intracramal
traumatic
renal failure
suicide
digestive tract
postoperatively
carcinoma
other
Stroke syndrome
Neoplasm
Suicide
Myocardial infarction
Renal failure
Allergie reaction
Unknown
Total
No of deaths
20b
3
6L
2d
ld
1
1
2d
4
3C
15
2
1
3
1
3f
43
d
 In all but four cases causes of death were
obtamed from physicians m the remammg
cases from famüy members
'' Five cases also counted under causes
beneath, mdicated by note (d)
c
 Accompamed with head injury m three to
five cases
d
 Also counted under specified heading
below
c
 Haemorrhage or thrombosis unknown
(aged 53, 78, 82 years)
f
 Aged 23, 43 and 48 years
Cause
Observed/
Expected expected 9 5% confidence
number ratio interval
Neoplasm
Lung cancer
Accidents
Suicide
Stroke syndrome
Renal failure
5 9
0 7
2 3
0 8
1 2
0 1
2 5
8 6
2 6
2 5
5 0
30 0
1 4-4 2
3 1-18 7
1 0-5 7
0 3-9 0
1 8 10 9
6 0-88 0
Ischaemic heart disease 5 0 0 2 0 0-1 l
* The expected number of deaths was calculated by patient-year
analysis, the observed/expected ratio is the standardized mortahty
ratio (SMR) The 95% confidence interval apphes to this ratio
not statistically sigmficant, but the power to detect such a
difference was weak, due to the small number of deaths
Causes of death could be obtamed m 40 out of 43 deceased
patients (Table III) At least 20 deaths were caused by
haemorrhage, although m several patients an underlymg
lethal disorder existed Traumatic bleedmg was the most
orevalent. One death was caused by an allergic reaction to
cryoprecipitate with glotüs oedema, m three deaths the cause
was renal disease, a frequent comphcation in haemophilia
(Prentice et al, 1971; Lazerson, 1976). No other therapy-
associated deaths occurred: no cases of AIDS among haemo-
phihacs were known in the Netherlands at the end of the
follow-up penod and none of the reported death causes could
be attnbuted to AIDS Specifically, there were no tumours of
lymphatic tissue or opportumstic mfections Surpnsmgly, no
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deaths caused by liver disease were reported. All deaths in
Inhibitor patients were caused by bleeding. Five of the 11
deaths in patients with severe haemophilia not treated
prophylactically were associated with haemorrhage, but
none of the three deaths in the patients receiving prophylaxis.
Patient-year analysis provided the age adjusted expected
number of deaths for each cause (Table IV). This showed a
higher-than-expected mortality of several causes that are not
(directly) associated with the bleeding tendency. For neo-
plasms the observed number of deaths was 2-5 times the
expected number. More than half of this excess cancer
mortality was caused by lung tumours. In sharp contrast to
this, the number of deaths from ischaemic heart disease was
lower than the calculated expected number: while flve were
expected only one was observed, a signiflcant reduction
(P—0-03, one-sided test). This low mortality due to is-
chaemic heart disease occurred in the face of a high
prevalence of hypertension, at least äs judged by the use of
antihypertensive medication. In our latest survey we found
26% of the severely affected patients aged 40-65 to use
antihypertensive drugs, compared to 8% in moderate and
mild haemophilia.
DISCUSSION
Our results indicate a mortality risk in haemophilia that is
twice the risk that applies to the general male population.
This implies an enormous advance compared to only a few
decades ago, but still leads to a calculated loss of 8 years on
median life expectancy. Most improvement has been made in
severe haemophilia, and hence the death rates in severe,
moderate and mild haemophilia were not very different.
Inhibitor patients had a far less favourable prognosis.
Analysis of the causes of death revealed a very low occur-
rence of deaths due to ischaemic heart disease, while an
excess of neoplastic deaths, especially from lung cancer, was
observed.
The patient group of this study was formed by the
respondents of our mail surveys of 1973 and 1978. Because
of the high overall response rate of 79% and the long period of
follow-up we do not think that non-response introduced an
important bias. It is likely, however, that selection occurred
before the questionnaires were sent in the acquisition of
addresses from the major haemophilia care centres and the
Dutch Haemophilia Society. Patients with mild haemophilia
probably are underrepresented, since their disease may
remain undetected for many years if not for life and,
moreover, because many of these patients are not registered
in a major haemophilia centre.
We are confldent that the acquisition of addresses of the
severely affected patients was fairly complete. The 321
patients with severe haemophilia were included by sending
questionnaires to over 400 patients. If these were all patients
with severe haemophilia living in 1979, the prevalence of
severe haemophilia would be 3-1/100000, which is similar
to (Rizza & Spooner, 1983) or higher than (Larsson et al,
1982) flgures from reports from countries with excellent
registration Systems. For our 1986 survey we carried out a
far more extensive search, also including many small
hospitals. This study, in our judgement, includes practically
all known Dutch haemophiliacs. Our efforts, however, did not
lead to an increased number of addresses of patients with
severe haemophilia, whereas 50% more patients with mild
haemophilia were included. This implies that selection was
limited to mild haemophilia.
Prophylactic Substitution therapy possibly reduces mor-
tality in comparison to Όη-demand' treatment. Intensive
therapy also carries the risk of transfusion-transmitted
diseases. In our study deaths from AIDS or liver disease were
absent. The prevalence of antibodies to the human immuno-
deficiency virus (HIV) among Dutch haemophiliacs is lower
than in many other countries: 21% for severe haemophilia
(Rosendaal et al, 1988). This is most likely due to the
predominant use of plasma products from local nonpaid
donors and a large use of cryoprecipitate in The Netherlands.
As Wolfs et al (1988) pointed out, about half of the
seroconversions occurred after 1983, which serves äs a
further explanation for the absence of AIDS cases up to l *
January 1986.
Aronson (1988), reporting on almost 1000 deaths of
U.S.A. haemophiliacs from 1968 to 1979, found 9% of deaths
to be caused by liver disease. Among 107 deaths of haemo-
philia patients in Great Britain between 1976 and 1980, 2%
died of liver disease, while about half of the patients were
treated with commercially produced plasma products (Rizza
& Spooner, 1983). These data suggest that the origin of the
clotting factor preparations plays a role in the prevalence of
liver disease, äs has been reported by Spero et al (1979).
Aledort et al (1985), however, found no association between
the occurrence of severe liver disease and the product used.
We observed a large excess of cancer deaths, which was in
part caused by neoplasms of the lung. Since the chance of
surviving a carcinoma of the lung is generally low, this can
only be fully explained by a raised incidence. A simple
hypothesis is that haemophiliacs smoke more often than
others, which might be related to their physical disability.
The administration of blood transfusion during surgery has
been reported to lead to less rejections of renal transplants ^
(Opelz et al, 1973), and higher recurrence rates of malignan-*
cies (Burrows & Tarttes, 1982), possibly caused by immuno-
suppression. Immune alterations have also been demon-
strated in poly-transfused haemophiliacs (Brettler et al, 1986;
Madhok et al, 1986). Although the role of the clotting system
in metastasis is a matter of controversy (Bastida, 1985), it
may well be possible that the absence of fibrin formation
around microscopic tumours enhances early metastasis in
haemophilia patients which, combined with immune abnor-
malities, raises the cancer incidence.
The relative mortality due to ischaemic heart disease was
significantly lower in haemophiliacs than in the general male
population. This reduction is remarkable when viewed in the
light of the raised mortality of many other causes. The high
prevalence of hypertension among haemophiliacs makes this
finding even more impressive. Autopsy series have shown
that haemophilia does not prevent the development of
atherosclerosis (Dalldorf et al, 1981; Small et al, 1983).
Consequently, we think that delayed fibrin formation may
protect patients with haemophilia against coronary throm-
bosis and myocardial infarction (DeWood et al, 1980; Report
of the Sixty-plus Reinfarction Study Research Group, 1980).
This protection is only partial, since myocardial infarction in
haemophiliacs has been reported occasionally (Boivin, 1954;
Borchgrevink, 1959). Three earlier reports on deaths in
haemophilia, together reporting on more than 200 deaths,
also seem to show a deflcit of deaths by myocardial infarction
(Johnson et al, 1985; Rizza & Spooner, 1983; Schiller et al,
1985), although we were not able to calculate the combined
observed-expected ratio from the published data. One report,
covering 118 deaths over the period 1957-80 in Sweden,
does not show a deficit (Larsson & Wiechel, 1983). Aronson
(1988) found an inversed ratio of the number of cancer
deaths over the number of deaths from ischaemic heart
disease, suggestive of a decreased mortality from heart
disease or an increased cancer mortality, or both. Since the
life expectancy of haemophiliacs is gradually becoming
normal, more patients will live to experience diseases of the
elderly like ischaemic heart disease and a deficit will be easier
to observe.
When studying mortality over a 13-year interval, recent
changes are not reflected fully in the data. In the last few
years, inhibitor patients have received treatment with low
dose Substitution therapy which leads to the disappearance of
many inhibitors (Van Leeuwen et al, 1986). Therefore, it is
likely that the prognosis for these patients is far better now
than during the years of our study. In the immediate future
AIDS, äs well äs liver disease, will have an effect on mortality,
the impact of which may differ from country to country.
However devastating, these effects will be temporary. For the
future we expect the disappearance of possible carry-over
effects from the past, when more and more patients will have
received adequate therapy from childhood.
ACKNOWLEDGMENTS
»
We gratefully acknowledge the cooperation of the patients
and the haemophilia treatment centres that made this study
possible. Dr W. A. van Stiphout kindly gave her advice. Mrs
R. M. Claassen-Tegelaar diligently prepared the manuscript.
This study was made possible by flnancial support from Het
Praeventiefonds (28-1099) and De Stichting Haemophilia.
REFERENCES
Aledort, L.M., Levine, P.H., Hilgartner, M., Blatt, F., Spero, J.A.,
Goldberg, J.D., Bianchi, L., Desmet, V„ Scheuer, P., Popper, H. &
Berk, P.D. (1985) A study of liver biopsies and liver disease among
hemophiliacs. Blood, 66, 367-372.
Aronson, D.L. (1988) Cause of death in hemophilia A patients in the
United States from 1968 to 1979. American Journal ofHematology,
27, 7-12.
Bastida, E. (1985) The metastatic cascade: potential approaches for
the Inhibition of metastasis. Seminars in Thrombosis and Hemostasis,
14, 66-72.
Mortality in Dutch Haemophiliacs, 1973-86 75
Boivin, J.M. (1954) Infarctus du myocarde chez un heraophile. Mal
du Coeur, 47, 351-354.
Borchgrevink, C.F. (1959) Myocardial infarction in a haemophiliac.
Lancet, i, 1129-1230.
Brettler, D.B., Forsberg, A.D., Brewster, F., Sullivan, J.L. & Levine,
P.H. (1986) Delayed cutaneous hypersensitivity reactions in
hemophiliac subjects treated with factor concentrate. American
Journal of Medicine, 81, 607-611.
Burrows, L. & Tartter, P. (1982) Effect of blood transfusion on colonic
malignancy recurrence rate. Lancet, ii, 662.
Dalldorf, F.G., Taylor, R.E. & Blatt, P.M. (1981) Arteriosclerosis in
severe hemophilia: a postmortem study. Archives of Pathology and
Laboratory Medicine, 105, 652-654.
DeWood, M.A., Spores, J., Notske, R., Mouser, L.T., Burroughs, R.,
Golden, M.S. & Lang, H.T. (1980) Prevalence of total coronary
occlusion during the early hours of transmural myocardial
infarction. New England Journal of Medicine, 303, 897-902.
Ikkala, E„ Helske, T., Myllyla, G., Nevanlinna, H.R., Pitkanen, P. &
Rasi, V. (1982) Changes in the life expectancy of patients with
severe haemophilia in Finland in 1930-79. British Journal of
Haematology, 52, 7-12.
Johnson, R.E., Lawrence, D.N., Evatt, B.L., Bregman, D.J., Zyla, L.D.,
Curran, J.W., Aledort, L.M., Eyster, M.E., Brownstein, A.P. &
Carman, C.J. (1985) Acquired immunodeficiency syndrome
among patients attending hemophilia treatment centers and
mortality experience of hemophiliacs in the United States. Ameri-
can Journal of Epidemiology, 121, 797-810.
Larsson, S.A., Nilsson, I.M. & Blomback, M. (1982) Current Status of
Swedish hemophiliacs. Acta Medien Scandinavica, 212, 195-200.
Larsson, S.A. & Wiechel, B. (1983) Deaths in Swedish hemophiliacs,
1957-1980. Acta Medica Scandinavica, 214, 199-206.
Larsson, S.A. (1985) Life expectancy of Swedish haemophiliacs,
1831-1980. British Journal of Haematology, 59, 593-602.
Lazerson, J. (1976) Renal disease in hemophilia. Hemophilia in
Children (ed. by M. W. Hilgartner), pp. 71-78. Acton Mass
Publishing Sciences Group, Acton.
Madhok, R., Gracie, A., Löwe, G.D.O., Burnett, A., Froebel, K., Follett,
E. & Forbes, C.D. (1986) Impaired cell mediated immunity in
haemophilia in the absence of infection with human immunodefi-
ciency virus. British Medical Journal, 293, 978-980.
Netherlands Central Bureau of Statistics (CBS) (1973-86) Overlede-
nen naar doodsoorzaak, leeftijd en geslacht (Mortality by cause,
age and sex): series AI and Bl. Staatsuitgeverij, The Hague.
Netherlands Central Bureau of Statistics (CBS) (1984) Life table by
marital Status, 1976-1980. Table 3B, p. 67. Staatsuitgeverij, The
Hague.
Nour-Eldin, F. (1961) Longevity of haemophiliacs. British Medical
Journal, i, 824.
Opelz, G., Sengar, D.G.S., Mickey, M.R. &Terasaki, P.I. (1973) Effects
of blood transfusion on subsequent kidney transplants. Transplan-
tation Proceedings, 5, 253-259.
Prentice, C.R.M., Lindsay, R.M., Barr, R.D., Forbes, C.D., Kennedy,
A.C., McNicoI, G.P. & Douglas, A.S. (1971) Renal complications in
haemophilia and Christmas disease. Quarterly Journal of Medicine,
157,47-61.
Ramgren, 0. (1962) Haemophilia in Sweden: pari 2. Acta Medica
Scandinavica (Suppl.), 937s, 37-60.
Report of the Sixty-plus Reinfarction Study Research Group (19 80) A
double blind trial to assess long-term oral anticoagulant therapy in
elderly patients after myocardial infarction. Lancet, ii, 989-994.
Rizza, C.R. & Spooner, R.J.D. (1983) Treatment of haemophilia and
related disorders in Britain and Northern Ireland during 1976-
1980: report on behalf of the directors of haemophilia centres in
the United Kingdom. British Medical Journal, 286, 929-933.
Rosendaal, F.R., Smit, C., Varekamp, L, Bröcker-Vriends, A., Suur-
76 F. Rosendaal et al
meijer, T P B M & Briet, E (1988) AIDS and haemophilia a study
among Dutch haeraophihacs on the psychosocial impact of the
AIDS threat, the prevalence of HIV antibodies and the adoption of
measures to prevent HIV transmission Haemostasi'; 18,73-82
Schiller, W G , Hartmann G & Rerade, W (1985) Todesursachen
von Haraophihepatienten m der DDR Foiia Haematologica (Leip-
zig) 112,845-852
S]olm, K E (1960) Raemophüic Diseases m Denmark Blackwell
Scientific Pubhcations, Oxford
Small, M Jack, A S , Löwe, G D 0 , Mutch, A Γ Forbes C D &
Prentice, C R M (1983) Coronary artery disease m haemophilia
EntKh Heart Journal 49, 604-607
Spero, J A Lewis, J H Fisher, S E , Hasiba, U & Van Thiel D H
(1979) The high nsk of chronic liver disease m multitransfused
juvemle hemophihac patients Journal of Pediatncs 94,875-878
Van Leeuwen, E F , Van Dijken, P J , Mauser-Bunschoten, E P , Kok,
A J Sjamsoedm-Visser E J M &Sixma,JJ (1986) Disappearance
of factor VIII C antibodies in patients with haemophiha A upon
frequent admimstration of factor VIII m intermediate or low dose
ßntish Journal of Haematology 24, 291-294
Wolff, L J , Dwyer, C A & Lovrien E W (1986) Deaths m Oregon
hemophiliacs (Abstract) Chmcal Rewarch, 34, 125A
Wolfs T F W , Breederveld, C Krone W J A Van den Hoek L ,
Bakker M Smit L Goudsmit, J & the Dutch haemophilia group
(1988) HlV-antibody seroconversions in Dutch haemophiliacs
usmg heat-treated and non hcat-treated coagulation factor con
centrates Thrombosis and Haemostasis, 59, 396 399
